Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 04/17/18
End: 05/29/19
Due: 05/29/20
Phase: N/A
Priority: Normal
Start: 02/28/15
End: 12/31/24
Due: 12/31/25
Clinical Endpoint Bioequivalence Study of Fluticasone Propionate & Salmeterol Xinafoate (100μg/50μg)
Phase: N/A
Priority: Normal
Start: 04/26/18
End: 09/10/19
Due: 09/10/20
Phase: N/A
Priority: Normal
Start: 11/30/10
End: 04/30/16
Due: 04/30/17
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Study of Oral Morphine Sulfate Administration in Pediatric Subjects | NCT03429400 | West-Ward Pharmaceutical | user2@example.com | None | 2018-04-17 | 2019-05-29 | 2020-05-29 | - | - | 2025-07-14 |
| Study to Determine the Pharmacokinetics and Pharmacodynamic Effects of Phenylephrine on BP Via IV | NCT02323399 | West-Ward Pharmaceutical | user2@example.com | None | 2015-02-28 | 2024-12-31 | 2025-12-31 | - | - | 2025-07-14 |
| Clinical Endpoint Bioequivalence Study of Fluticasone Propionate & Salmeterol Xinafoate (100μg/50μg) | NCT03535870 | West-Ward Pharmaceutical | user2@example.com | None | 2018-04-26 | 2019-09-10 | 2020-09-10 | - | - | 2025-07-14 |
| Evaluation Phenobarbital as Adjunctive Therapy in Participants With Partial Onset Seizures | NCT01284556 | West-Ward Pharmaceutical | user2@example.com | None | 2010-11-30 | 2016-04-30 | 2017-04-30 | - | - | 2025-07-14 |